Continuous Renal Replacement Therapy Market - Databook 2025 to 2034

The global continuous renal replacement therapy market size surpassed USD 1.61 billion in 2024 and is predicted to reach around USD 3.61 billion by 2034, registering a CAGR of 8.4% from 2025 to 2034.

Highlights of Continuous Renal Replacement Therapy Market

• By region, North America dominated the global continuous renal replacement therapy market in 2024.
• By region, Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
• By product, the consumables segment held a dominant presence in the continuous renal replacement therapy market in 2024.
• By product, the system segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
• By modality, the continuous venovenous hemofiltration (CVVH) segment accounted for a considerable share of the continuous renal replacement therapy market in 2024.
• By modality, the continuous venovenous hemodiafiltration (CVVHDF) segment is projected to experience the fastest rate of market growth from 2025 to 2034.

Industry Valuation and Growth Rate Projection

Continuous renal replacement therapy is the term used to include life-supporting treatments for renal failure. Renal replacement therapy replaces the non-endocrine kidney function in patients with renal failure. Continuous renal replacement therapy (CRRT) is used in the intensive care unit when a patient’s kidneys are not functioning properly. It is a form of dialysis that removes excess fluids, wastes, and toxins. Technologies include peritoneal dialysis, hemodialysis, continuous hemofiltration, and intermittent hemodialysis. Research & development (R&D) spending by key industry players and an increasing senior population are more susceptible to kidney failure, driving the growth of the continuous renal replacement therapy market.

According to a report published by the International Society of Nephrology, globally, more than 850 million people suffer from some form of kidney disease, which is increasing every year. The prevalence of chronic kidney disease (CKD) worldwide is 10.4% among men and 11.8% among women.

Continuous Renal Replacement Therapy: Stats and Figures

• According to a report published on the global epidemiology of end-stage kidney disease, the unadjusted 5-year survival of ESKD patients on kidney renal therapy (KRT) was 41% in the USA, 48% in Europe, and 60% in Japan.
• In 2020, the World Health Organization (WHO) ranked chronic kidney disease (CKD) as the 10th leading cause of death. Chronic kidney disease (CKD) affects 11.7% to 15.1% (13.4%) of the world’s population.

How has AI Benefited the Continuous Renal Replacement Therapy Market?

Artificial intelligence (AI)-based tools have the potential to improve and facilitate continuous renal replacement therapy (CRRT) delivery. Recent research has mostly focused on the ML-based model's development for the early identification of patients who need CRRT, and their risk classification of mortality or kidney recovery. AI functions in kidney disease include evaluating prognosis, guiding treatment, diagnostic assistance, and altering systems. By analyzing enormous databases, AI can offer new insights that can transform the operational environment in many ways. It can allow preoperative risk assessment and enable a better selection of candidates for procedures like organ transplantation.

Industry Leader Announcements

• Jose (Joe) E. Almeida to retire as Chair, President, and Chief Executive Officer

In February 2025, Jose (Joe) E. Almeida, the Chair, President, and Chief Executive Officer (CEO), will retire from his executive roles with the company, effective immediately, announced by a global medtech leader, Baxter International Inc.

• Michael Sen, Chairman of the Supervisory Board of Fresenius Medical Care Management AG

In October 2023, Michael Sen, Chairman of the Supervisory Board of Fresenius Medical Care Management AG, said, “We are delighted to have Craig Cordola join the Management Board of Fresenius Medical Care as the leader of the global Care Delivery Organization. Craig has a wealth of knowledge and experience managing large healthcare systems and organizations. With this expertise, he will be a crucial player in the Management Board in implementing Fresenius Medical Care’s turnaround and focusing on patient care.”

Geographical Insights

North America dominated the global continuous renal replacement therapy market in 2024. R&D spending by key industry players, investment in innovative medical technologies, and an increasing senior population are more susceptible to kidney failure, are driving the growth of the market in the North American region.

Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period. Rising awareness of advanced renal care, high prevalence of renal diseases, rising healthcare expenditure, and growing healthcare infrastructure are driving the growth of the continuous renal replacement therapy market.

Recent Developments in the Continuous Renal Replacement Therapy Market

• In March 2024, a new ‘Augmented Reality’ (AR) application to make learning easier for nursing staff in Kidney Replacement Therapy in Intensive Care Units was launched by the world’s leading provider of products and services for individuals with renal diseases, Fresenius Medical Care (FME).
• In December 2020, the U.S. Commercial launch of the Carpediem Cardio-Renal Pediatric Dialysis Emergency Medicine was announced by Medtronic Plc. The U.S. Food and Drug Administration’s (FDA) marketing authorization was granted, the first Carpediem system in the United States was successfully installed and is in use at Cincinnati Children’s Hospital Medical Center.

Competitive Landscape

• Company Name: Baxter International Inc.
• Year of Incorporation: 1931
• Headquarters: Deerfield, Illinois, United States

There are over 100 countries where it operates. It operates primarily in the healthcare sector, especially in surgical, hospital, nutritional, and acute care products, which help to advance healthcare around the world.

• Company Name: Fresenius Medical Care AG & Co. KGaA
• Year of Incorporation: 1996
• Headquarters: Bad Homburg v. d. Hohe, Germany

The company operates in around 100 countries. They operated around 40 production sites on all continents to provide dialysis products like dialyzers, dialysis machines, and related disposables. It operates primarily in the healthcare industry, especially in kidney care and dialysis.

Total Baxter worldwide sales for Q3 2024 were $3.85 billion, which include continuous operations sales of $2.70 billion and discontinued operations sales of $1.15 billion.